Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Minocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | USP2 | O75604 | 4/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | GRK6 | P43250 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | ALB | P02768 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minocycline SCHEMBL9340562 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL13520108 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL1820770 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL13520109 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL1917128 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL13520116 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL22171064 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL20716523 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL21931671 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL11911315 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020255983-A1 | MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mPTP)-OPENING INHIBITOR, NOVEL COMPOUND EXHIBITING mPTP-OPENING INHIBITORY ACTIVITY, AND USE THEREFOR | 国立研究開発法人理化学研究所 | 2020-12-24 | — | — | WO | disclosed |
| WO-2020079570-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING A GROWTH RELATED DISEASE AND/OR A CLINICAL CONDITION THEREOF | Ck Biotechnology Co. (KR) | 2020-04-23 | — | — | WO | disclosed |
| US-9896422-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Neumedics (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896422-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Neumedics (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170144979-A1 | TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS | Neumedics (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170144979-A1 | TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS | Neumedics (US) | 2017-05-25 | — | — | US | disclosed |
| US-9573912-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Neumedics (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160009668-A1 | TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS | Neumedics (US) | 2016-01-14 | — | — | US | disclosed |
| US-9168265-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Neumedics | 2015-10-27 | — | — | US | disclosed |
| US-9168265-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Neumedics | 2015-10-27 | — | — | US | disclosed |
| US-8338477-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Neumedics (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338477-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Neumedics (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2327687-A2 | Methods of preparing substituted tetracyclines with transition metal-based chemistries | TRUSTEES OF TUFTS COLLEGE (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100009981-A1 | Tetracycline Derivatives with Reduced Antibiotic Activity and Neuroprotective Benefits | Neumedics (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009981-A1 | Tetracycline Derivatives with Reduced Antibiotic Activity and Neuroprotective Benefits | Neumedics (US) | 2010-01-14 | — | — | US | disclosed |
| US-20070049562-A1 | Tigecycline and methods of preparation | WYETH | 2007-03-01 | — | — | US | disclosed |
| US-20070049562-A1 | Tigecycline and methods of preparation | WYETH | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009981-A1 | Tetracycline Derivatives with Reduced Antibiotic Activity and Neuroprotective Benefits | DCX, CASP3, BCL2 | TDP1 610/4885KDM4E 1640/4885USP2 2712/4885 |
| US-20070049562-A1 | Tigecycline and methods of preparation | TET3, TET1, TYMS | TDP1 802/4885KDM4E 1132/4885USP2 2552/4885 |
| US-20160009668-A1 | TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS | DCX, CASP3, BCL2 | TDP1 610/4885KDM4E 1640/4885USP2 2712/4885 |
| US-20170144979-A1 | TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS | DCX, CASP3, BCL2 | TDP1 610/4885KDM4E 1640/4885USP2 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.